Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma

• Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Sherry, Rubinstein, Maria M., Park, Kay J., Konner, Jason A., Makker, Vicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365456/
https://www.ncbi.nlm.nih.gov/pubmed/34430690
http://dx.doi.org/10.1016/j.gore.2021.100844
Descripción
Sumario:• Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab. • Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study.

Ejemplares similares